Pablo Laborda

Mr. Pablo Laborda

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2023 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
FSFernando Sanz
Fernando Sanz
TGTERESA GIL-GIL
TERESA GIL-GIL
PLPablo Laborda
Pablo Laborda
PBPaula Blanco
Paula Blanco
LOLuz Edith Ochoa-Sánchez
Luz Edith Ochoa-Sánchez
SHSara Hernando-Amado
Sara Hernando-Amado

Verified
Journal Article
Open access
PDF file
FSFernando Sanz
Fernando Sanz
TGTERESA GIL-GIL
TERESA GIL-GIL
PLPablo Laborda
Pablo Laborda
LOLuz Edith Ochoa-Sánchez
Luz Edith Ochoa-Sánchez
JMJose Martinez
Jose Martinez
SHSara Hernando-Amado
Sara Hernando-Amado
The use and misuse of antibiotics have made antibiotic-resistant bacteria widespread nowadays, constituting one of the most relevant challenges for human health at present. Among these bacteria, opportunistic pathogens with an environmental, non-clinical, primary habitat stand as an increasing matter of concern at hospitals. These organisms usually present low susceptibility to antibiotics currently used for therapy. They are also proficient in acquiring increased resistance levels, a situation that limits the therapeutic options for treating the infections they cause. In this article, we analyse the most predominant opportunistic pathogens with an environmental origin, focusing on the mechanisms of antibiotic resistance they present. Further, we discuss the functions, beyond antibiotic resistance, that these determinants may have in the natural ecosystems that these bacteria usually colonize. Given the capacity of these organisms for colonizing different habitats, from clinical settings to natural environments, and for infecting different hosts, from plants to humans, deciphering their population structure, their mechanisms of resistance and the role that these mechanisms may play in natural ecosystems is of relevance for understanding the dissemination of antibiotic resistance under a One-Health point of view.

30 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SHSara Hernando-Amado
Sara Hernando-Amado
PLPablo Laborda
Pablo Laborda
JMJose Martinez
Jose Martinez
Collateral sensitivity (CS) is an evolutionary trade-off traditionally linked to the mutational acquisition of antibiotic resistance (AR). However, AR can be temporally induced, and the possibility that this causes transient, non-inherited CS, has not been addressed. Mutational acquisition of ciprofloxacin resistance leads to robust CS to tobramycin in pre-existing antibiotic-resistant mutants of Pseudomonas aeruginosa. Further, the strength of this phenotype is higher when nfxB mutants, over-producing the efflux pump MexCD-OprJ, are selected. Here, we induce transient nfxB-mediated ciprofloxacin resistance by using the antiseptic dequalinium chloride. Notably, non-inherited induction of AR renders transient tobramycin CS in the analyzed antibiotic-resistant mutants and clinical isolates, including tobramycin-resistant isolates. Further, by combining tobramycin with dequalinium chloride we drive these strains to extinction. Our results support that transient CS could allow the design of new evolutionary strategies to tackle antibiotic-resistant infections, avoiding the acquisition of AR mutations on which inherited CS depends.

6 April 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SHSara Hernando-Amado
Sara Hernando-Amado
PLPablo Laborda
Pablo Laborda
JVJose R Valverde
Jose R Valverde
JMJose Martinez
Jose Martinez
Significance: Bacterial adaptation to the presence of an antibiotic often involves evolutionary trade-offs, such as increased susceptibility to other drugs (collateral sensitivity). Its exploitation to design improved therapeutic strategies is only feasible if collateral sensitivity is robust, reproducible, and emerges in resistant mutants; these issues are rarely addressed in available publications. We describe a robust collateral sensitivity phenotype that emerges in different antibiotic-resistance mutational backgrounds, due to different genetic events, and propose therapeutic strategies effective for treating infections caused byPseudomonas aeruginosaantibiotic-resistant mutants. Since conserved collateral sensitivity phenotypes do not confer adaptation to the presence of antibiotics, our results are also relevant for understanding convergent evolution processes in which the force selecting the emerging phenotype remains unclear.

22 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
PLPablo Laborda
Pablo Laborda
SLSigne Lolle
Signe Lolle
SHSara Hernando-Amado
Sara Hernando-Amado
MAManuel Alcalde-Rico
Manuel Alcalde-Rico
KAKasper Aanæs
Kasper Aanæs
HJHelle Krogh Johansen
Helle Krogh Johansen
Mutations in mexZ, encoding a negative regulator of the expression of the mexXY efflux pump genes, are frequently acquired by Pseudomonas aeruginosa at early stages of lung infection. Although traditionally related to resistance to the first-line drug tobramycin, mexZ mutations are associated with low-level aminoglycoside resistance when determined in the laboratory, suggesting that their selection during infection may not be necessarily, or only, related to tobramycin therapy. Here, we show that mexZ-mutated bacteria tend to accumulate inside the epithelial barrier of a human airway infection model, thus colonising the epithelium while being protected against diverse antibiotics. This phenotype is mediated by overexpression of lecA, a quorum sensing-controlled gene, encoding a lectin involved in P. aeruginosa tissue invasiveness. We find that lecA overexpression is caused by a disrupted equilibrium between the overproduced MexXY and another efflux pump, MexAB, which extrudes quorum sensing signals. Our results indicate that mexZ mutations affect the expression of quorum sensing-regulated pathways, thus promoting tissue invasiveness and protecting bacteria from the action of antibiotics within patients, something unnoticeable using standard laboratory tests.

14 November 2019 in Microbiologyopen
Verified
Journal Article
Open access
PDF file
TGTeresa Gil‐Gil
Teresa Gil‐Gil
PLPablo Laborda
Pablo Laborda
FSFernando Sanz‐García
Fernando Sanz‐García
SHSara Hernando-Amado
Sara Hernando-Amado
PBPaula Blanco
Paula Blanco
JMJose Martinez
Jose Martinez
Infectious diseases still stand as a major cause of morbidity and mortality, and this problem can be worsened with the current antimicrobial resistance crisis. To tackle this crisis more studies analyzing the causes, routes, and reservoirs where antimicrobial resistance can emerge and expand, together with new antimicrobials and strategies for fighting antimicrobial resistance are needed. In the current special issue of MicrobiologyOpen, a set of articles dealing with the multiple faces of antimicrobial resistance are presented. These articles provide new information for understanding and addressing this problem.